Seattle Genetics to comply with UN drugs to THE FDA (Reuter)
LOS ANGELES (Reuters)-a pivotal trial of experimental cancer targeting antibody Seattle Genetics for sick and UN Crowfoot Hodgkin the study found that more than a third country realized all point reduction of cancer. The company also said he hopes to submit the drug, brentuximab vedotin, u. s. regulator in the first half of next year for the sick and night Crowfoot Hodgkin or the UN UN large cell anaplastic (ALCL) who suspended in response to other thérapies. The company was a précédemment soumission would in the first half of 2011. Was '' our goal should submit in the first season, there is a review accéléré economic and trade market in 2011, "Chief Executive of Clay Siegall Seattle genetics said in an interview by telephone. Judging by vedotin brentuximab compared with another drug, but rate reduction on all fronts for patients in the same way tends, Pasco Bachelor, he said. The company developed UN drug and medicine Takeda Co., Japan and European regulators to discuss ...